Stockwinners Market Radar for October 02, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:04 EDT Fly Intel: Top five weekend stock stories - Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Tesla (TSLA) reported Q3 deliveries of 343,830, with 3% subject to operating lease accounting, and production of 365,923 vehicles. Tesla delivered 18,672 Model S/X and 325,158 Model 3/Y. The company said that, "Historically, our delivery volumes have skewed towards the end of each quarter due to regional batch building of cars. As our production volumes continue to grow, it is becoming increasingly challenging to secure vehicle transportation capacity and at a reasonable cost during these peak logistics weeks. In Q3, we began transitioning to a more even regional mix of vehicle builds each week, which led to an increase in cars in transit at the end of the quarter. These cars have been ordered and will be delivered to customers upon arrival at their destination." 2. Moderna (MRNA) has refused to hand over to China the core intellectual property behind the development of its breakthrough COVID-19 vaccine, leading to a collapse in negotiations on its sale there, Financial Times; Sun Yu, Eleanor Olcott and Donato Paolo Mancini report, citing people familiar with the matter. The company turned down Beijing's request to hand over the recipe for its messenger RNA vaccine because of commercial and safety concerns, said two people involved in negotiations that took place between 2020 and 2021. The vaccine maker says it is still "eager" to sell the product to China, the authors wrote. The mRNA vaccine technology used by Moderna and BioNTech (BTNX)/Pfizer (PFE) provides longer-lasting and higher levels of protection than the inactivated vaccine technology used by Chinese makers. Several Chinese pharma companies are racing to develop a homemade mRNA alternative but have struggled with the emergence of more infectious variants, the publication adds. 3. One year ago, investors couldn't get enough of special-purpose acquisition companies. Now, they can't dump SPACs fast enough, Al Root writes in this week's edition of Barron's. New technologies, new capital, and optimistic business projections had investors dreaming of big gains from these blank-check companies, like the 250% pop in 2020. Now that bubble has popped, the author notes. Many of the stocks got what they deserved after offering financial guidance that has proven wildly off the mark, but not every company has failed so spectacularly, the publication adds. Many look like solid companies that made the bad choice of coming to market via a SPAC, the author writes, such as Blue Owl Capital (OWL), ChargePoint (CHPT), Luminar (LAZR), Rocket Lab (RKLB), Vacasa (VCSA), and Vivid Seats (SEAT). 4. Paramount's (PARA) horror movie "Smile" on the weekend at the North America box office with a $22M debut from 3,645 locations. The film tells the story of a therapist who meets a graduate student who recently witnesses a gruesome suicide. Jessie T. Usher Kyle Gallner, Robin Weigert and Kal Penn co-star. 5. Olaplex Holdings (OLPX) and Deutsche Post DHL Group (DPSGY) saw positive mentions in this week's edition of Barron's.

14:11 EDT Tesla delivered 343,830 electric vehicles in Q3 - Tesla reported Q3 deliveries of 343,830, with 3% subject to operating lease accounting, and production of 365,923 vehicles. Tesla delivered 18,672 Model S/X and 325,158 Model 3/Y. The company said that, "Historically, our delivery volumes have skewed towards the end of each quarter due to regional batch building of cars. As our production volumes continue to grow, it is becoming increasingly challenging to secure vehicle transportation capacity and at a reasonable cost during these peak logistics weeks. In Q3, we began transitioning to a more even regional mix of vehicle builds each week, which led to an increase in cars in transit at the end of the quarter. These cars have been ordered and will be delivered to customers upon arrival at their destination."

14:00 EDT Cytokinetics presents new data from REDWOOD-HCM OLE - Cytokinetics announced new data on symptom improvement and quality of life related to treatment with aficamten in REDWOOD-HCM OLE in a Late Breaking Clinical Trials session at the Heart Failure Society of America Annual Scientific Meeting. Previously presented data from REDWOOD-HCM open label extension showed that treatment with aficamten was associated with significant and sustained reductions in left ventricular outflow tract gradient, improvements in New York Heart Association Functional Class and improvements in cardiac biomarkers. This new analysis evaluates patients' self-reported health status using the Kansas City Cardiomyopathy Questionnaire and compares baseline values to those collected at Week 12 and Week 24. The KCCQ is a validated patient reported outcomes tool1 used to evaluate heart failure symptoms and their impact on social and physical limitations as well as quality of life. Higher scores indicate better health status. As early as Week 12, patients experienced substantial and significant symptom improvements as measured by the change in their KCCQ scores. The KCCQ Overall Summary Score and all KCCQ sub-domain scores demonstrated these improvements, improvements which were also noted to be sustained through Week 24. In patients with heart failure with reduced ejection fraction, previous work has identified that worsening heart failure and lower left ventricular ejection fraction are risk factors for cardiovascular death and HF hospitalization. However, gaps remain in understanding the relative impact of these factors. A new analysis conducted in partnership with Yale University School of Medicine examined heart failure prevalence and rates of hospitalization. Reported statistics and U.S. 2020 Census data were used to estimate the prevalence of three groups of patients, including those with heart failure, those with HFrEF, and a third higher-risk subgroup of patients with heart failure with reduced ejection fraction with LVEF less than or equal to30%. Among these groups, patients were defined as having worsening heart failure if they had a heart failure event within the prior 6-12 months. Approximately 882 per 100,000 patients in the U.S. were estimated to have HFrEF including 634 per 100,000 with LVEF less than or equal to30%. Within the HFrEF subgroup, 168 per 100,000 patients had worsening heart failure, including 126 per 100,000 with LVEF less than or equal to30% and worsening heart failure and (7% of all patients with heart failure). Rates of heart failure hospitalizations were then estimated using reported event rates. Among the 343 heart failure hospitalizations per 100,000, 263 were for patients with worsening heart failure, suggesting that patients with worsening heart failure have a disproportionately high risk of HF hospitalization. Furthermore, the higher-risk subgroup with both worsening heart failure and LVEF less than or equal to30% comprised 7% of patients with heart failure, but accounted for 36% of all heart failure hospitalizations, an excess risk of 516% relative to the average patient with heart failure. This suggests that there remains significant unmet medical need among people with worsening heart failure.